BPIQ Blog

$XBI $91.77 | +2.13% Covid Updates $AZN +2.6% Evusheld long-acting antibody combination recommended for approval in the EU for the...

$XBI $89.86 | -2.55% Covid Updates $MRNA -4.3% Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 ...

$XBI $92.21 | +3.58% Covid Updates $NVAX +6.7% Novavax and Serum Institute of India Announce First Emergency Use Authorization of...

$XBI $89.02 | -3.41% Covid Updates $MRNA -2.0% Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven...

$XBI $92.16 | +2.9% Covid Updates $MRNA +6.3% MODERNA SUBMITS AMENDMENT TO THE EMERGENCY USE AUTHORIZATION FOR AN ADDITIONAL BOOSTER...

$XBI $89.56| +3.91% Covid Updates $MRNA -0.5% Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years) source $EIGR...

$XBI $86.19 | +4.79% Covid Updates $ Pipeline Updates $AZN +1.0% Lynparza reduced risk of death by 32% in the adjuvant treatment of...

$XBI $82.26 | +1.47% Covid Updates $PFE 0.0% Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster...

$XBI $81.07 | -4.18% Covid Updates $ADMP -6.1% Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the...

$XBI $84.53 | -3.9% Pipeline Updates $HARP -27.4% Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and...

$XBI $87.98 | -0.5% Covid Updates $MRNA -2.1% Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent...

$XBI $88.44 | +4.89% Covid Updates $ Pipeline Updates $NTLA +3.7% Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for...

$XBI $84.32 | +0.67% Covid Updates Pipeline Updates $AFMD +1.5% Affimed Announces Clinical Updates at the Annual Meeting of the American...

$XBI $83.76 | -0.17% Covid Updates Pipeline Updates $LVTX +1.4% LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO...

$XBI $83.90 | -3.17% Pipeline Updates $CHRS +2.5% Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal...

$XBI $86.65| -2.99% Pipeline Updates $GLSI -3.3% Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent...

$XBI $89.32 | +0.26% Pipeline Updates $TCDA +4.9% Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on...

$XBI $89.09 | Pipeline Updates $FNCH Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile...

$XBI $89.83 | +0.03% Covid Updates $NVAX +2.1% Novavax Announces Extended Durability of Protection Against Infection and Disease in...

$XBI $89.80 | +0.9% Pipeline Updates $RETA +2.2% Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone...